Moderate to Severe Asthma
11
5
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
36%
4 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
Phase II Trial of RC1416 Injection in Asthma
A Phase Ib Study of RC1416 Injection
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
A Study of CM310 in Subjects With Moderate to Severe Asthma
A Study of CM326 in Subjects With Moderate to Severe Asthma
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
Study of Multiple Ascending Dose of KBL693 in Healthy Participants